340 related articles for article (PubMed ID: 28455849)
1. Coupling I-125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological models.
Miksys N; Haidari M; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Med Phys; 2017 Aug; 44(8):4329-4340. PubMed ID: 28455849
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric and radiobiological investigation of permanent implant prostate brachytherapy based on Monte Carlo calculations.
Haidari AM; Miksys N; Soubiran P; Cygler JE; Holmes O; Perry G; Thomson RM
Brachytherapy; 2019; 18(6):875-882. PubMed ID: 31400953
[TBL] [Abstract][Full Text] [Related]
3. Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy.
Miksys N; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):606-615. PubMed ID: 28126308
[TBL] [Abstract][Full Text] [Related]
4. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
Butler WM; Stewart RR; Merrick GS
Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of dosimetric effects of metallic artifact reduction and tissue assignment on Monte Carlo dose calculations for
Assam I; Vijande J; Ballester F; Pérez-Calatayud J; Poppe B; Siebert FA
Med Phys; 2022 Sep; 49(9):6195-6208. PubMed ID: 35925023
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric investigation of
Deering SG; Hilts M; Batchelar D; Crook J; Thomson RM
Brachytherapy; 2021; 20(3):686-694. PubMed ID: 33551273
[TBL] [Abstract][Full Text] [Related]
7. Consequences of dose heterogeneity on the biological efficiency of ¹⁰³Pd permanent breast seed implants.
Afsharpour H; Reniers B; Landry G; Pignol JP; Keller BM; Verhaegen F; Beaulieu L
Phys Med Biol; 2012 Feb; 57(3):809-23. PubMed ID: 22252246
[TBL] [Abstract][Full Text] [Related]
8. Monte Carlo study of LDR seed dosimetry with an application in a clinical brachytherapy breast implant.
Furstoss C; Reniers B; Bertrand MJ; Poon E; Carrier JF; Keller BM; Pignol JP; Beaulieu L; Verhaegen F
Med Phys; 2009 May; 36(5):1848-58. PubMed ID: 19544804
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of low energy brachytherapy Monte Carlo dose calculations to uncertainties in human tissue composition.
Landry G; Reniers B; Murrer L; Lutgens L; Gurp EB; Pignol JP; Keller B; Beaulieu L; Verhaegen F
Med Phys; 2010 Oct; 37(10):5188-98. PubMed ID: 21089752
[TBL] [Abstract][Full Text] [Related]
10. Investigation of interseed attenuation and tissue composition effects in (125)I seed implant prostate brachytherapy.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Brachytherapy; 2014; 13(6):603-10. PubMed ID: 24913435
[TBL] [Abstract][Full Text] [Related]
11. Radiobiological parameters in a tumour control probability model for prostate cancer LDR brachytherapy.
Her EJ; Reynolds HM; Mears C; Williams S; Moorehouse C; Millar JL; Ebert MA; Haworth A
Phys Med Biol; 2018 Jun; 63(13):135011. PubMed ID: 29799812
[TBL] [Abstract][Full Text] [Related]
12. Development of virtual patient models for permanent implant brachytherapy Monte Carlo dose calculations: interdependence of CT image artifact mitigation and tissue assignment.
Miksys N; Xu C; Beaulieu L; Thomson RM
Phys Med Biol; 2015 Aug; 60(15):6039-62. PubMed ID: 26216174
[TBL] [Abstract][Full Text] [Related]
13. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
14. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
15. Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Med Phys; 2013 Mar; 40(3):031717. PubMed ID: 23464312
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric and radiobiological comparison of TG-43 and Monte Carlo calculations in
Peppa V; Pappas EP; Karaiskos P; Major T; Polgár C; Papagiannis P
Phys Med; 2016 Oct; 32(10):1245-1251. PubMed ID: 27720277
[TBL] [Abstract][Full Text] [Related]
17. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
Gagne NL; Leonard KL; Rivard MJ
Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
[TBL] [Abstract][Full Text] [Related]
18. An analytical model to determine interseed attenuation effect in low-dose-rate brachytherapy.
Safigholi H; Sardari D; Karimi Jashni S; Mahdavi SR; Meigooni AS
J Appl Clin Med Phys; 2013 May; 14(3):4226. PubMed ID: 23652254
[TBL] [Abstract][Full Text] [Related]
19. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
[TBL] [Abstract][Full Text] [Related]
20. Dose verification with Monte Carlo technique for prostate brachytherapy implants with (125)I sources.
Zhang H; Baker C; McKinsey R; Meigooni A
Med Dosim; 2005; 30(2):85-91. PubMed ID: 15922174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]